1
|
Blanco MJ, Bronson JJ, DiMauro EF, Dzierba C, Eggen M, Garner AL, Georg G, Giarolla J, Goodwin NC, Grenier-Davies MC, Haskell-Luevano C, Holzgrabe U, Huang R, Lagiakos HR, Leftheris K, Martin Y, Matos MJ, May-Dracka TL, Müller CE, Newman AH, Parmee E, Petter JC, Tamayo NA, Wexler RR, Bolognesi ML, Ripka A, Young W. Empowering Voices: Inspiring Women in Medicinal Chemistry. ACS Med Chem Lett 2024; 15:424-431. [PMID: 38628790 PMCID: PMC11017407 DOI: 10.1021/acsmedchemlett.4c00097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2024] [Indexed: 04/19/2024] Open
Abstract
As we celebrate International Women's Day 2024 with the theme "Inspire Inclusion", the women of the ACS Medicinal Chemistry Division (MEDI) want to foster a sense of belonging, relevance, and empowerment by sharing uplifting stories of what inspired them to become medicinal chemists. In this editorial, we are featuring female medicinal chemistry scientists to provide role models, encouragement, and inspiration to others. We asked women medicinal chemists to contribute a brief paragraph about what inspired them to become medicinal chemists or what inspires them today as medicinal chemists. The responses and contributions highlight their passions and motivations, such as their love of the sciences and their drive to improve human health by contributing to basic research and creating lifesaving drugs.
Collapse
|
2
|
Blanco MJ, Bronson JJ, DiMauro EF, Dzierba C, Eggen M, Garner AL, Georg G, Giarolla J, Goodwin NC, Grenier-Davies MC, Haskell-Luevano C, Holzgrabe U, Huang R, Lagiakos HR, Leftheris K, Martin Y, Matos MJ, May-Dracka TL, Müller CE, Newman AH, Parmee E, Petter JC, Tamayo NA, Wexler RR, Bolognesi ML, Ripka A, Young W. Empowering Voices: Inspiring Women in Medicinal Chemistry. J Med Chem 2024. [PMID: 38456628 DOI: 10.1021/acs.jmedchem.4c00493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2024]
Abstract
As we celebrate International Women's Day 2024 with the theme "Inspire Inclusion", the women of the ACS Medicinal Chemistry Division (MEDI) want to foster a sense of belonging, relevance, and empowerment by sharing uplifting stories of what inspired them to become medicinal chemists. In this editorial, we are featuring female medicinal chemistry scientists to provide role models, encouragement, and inspiration to others. We asked women medicinal chemists to contribute a brief paragraph about what inspired them to become medicinal chemists or what inspires them today as medicinal chemists. The responses and contributions highlight their passions and motivations, such as their love of the sciences and their drive to improve human health by contributing to basic research and creating lifesaving drugs.
Collapse
|
3
|
Kattar SD, Gulati A, Margrey KA, Keylor MH, Ardolino M, Yan X, Johnson R, Palte RL, McMinn SE, Nogle L, Su J, Xiao D, Piesvaux J, Lee S, Hegde LG, Woodhouse JD, Faltus R, Moy LY, Xiong T, Ciaccio PJ, Pearson K, Patel M, Otte KM, Leyns CEG, Kennedy ME, Bennett DJ, DiMauro EF, Fell MJ, Fuller PH. Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease. J Med Chem 2023; 66:14912-14927. [PMID: 37861679 DOI: 10.1021/acs.jmedchem.3c01486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
Genetic mutation of the leucine-rich repeat kinase 2 (LRRK2) protein has been associated with Parkinson's disease (PD), a disabling and progressive neurodegenerative disorder that is devoid of efficacious disease-modifying therapies. Herein, we describe the invention of an amidoisoquinoline (IQ)-derived LRRK2 inhibitor lead chemical series. Knowledge-, structure-, and property-based drug design in concert with rigorous application of in silico calculations and presynthesis predictions enabled the prioritization of molecules with favorable CNS "drug-like" physicochemical properties. This resulted in the discovery of compound 8, which was profiled extensively before human ether-a-go-go (hERG) ion channel inhibition halted its progression. Strategic reduction of lipophilicity and basicity resulted in attenuation of hERG ion channel inhibition while maintaining a favorable CNS efflux transporter profile. Further structure- and property-based optimizations resulted in the discovery of preclinical candidate MK-1468. This exquisitely selective LRRK2 inhibitor has a projected human dose of 48 mg BID and a preclinical safety profile that supported advancement toward GLP toxicology studies.
Collapse
Affiliation(s)
- Solomon D Kattar
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Anmol Gulati
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Kaila A Margrey
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Mitchell H Keylor
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Michael Ardolino
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Xin Yan
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Rebecca Johnson
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Rachel L Palte
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Spencer E McMinn
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Lisa Nogle
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Jing Su
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Dong Xiao
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Jennifer Piesvaux
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Susi Lee
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, New Jersey 07065, United States
| | - Laxminarayan G Hegde
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Janice D Woodhouse
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Robert Faltus
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Lily Y Moy
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Tina Xiong
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Paul J Ciaccio
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Kara Pearson
- Merck & Co., Inc., 770 Sumneytown Pike., West Point, Pennsylvania 19486, United States
| | - Mayankbhai Patel
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Karin M Otte
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Cheryl E G Leyns
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Matthew E Kennedy
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | | | - Erin F DiMauro
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Matthew J Fell
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Peter H Fuller
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| |
Collapse
|
4
|
Aldrich J, Allen S, Araujo E, Bronson J, Bryant-Friedrich A, Cyr SK, DiMauro EF, Dzierba C, Garner AL, Georg GI, Goodwin NC, Haranahalli K, Huang R, Leftheris K, May-Dracka TL, Olson ME, Blanco MJ. Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI). ACS Med Chem Lett 2023; 14:345-349. [PMID: 37077389 PMCID: PMC10107900 DOI: 10.1021/acsmedchemlett.3c00069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Indexed: 03/10/2023] Open
Abstract
On the occasion of the 2023 International Women's Day on March 8, 2023, we want to celebrate and highlight the contributions of many women volunteers in the American Chemical Society Division of Medicinal Chemistry (ACS MEDI).
Collapse
|
5
|
Aldrich J, Allen S, Araujo E, Bronson J, Bryant-Friedrich A, Cyr SK, DiMauro EF, Dzierba C, Garner AL, Georg GI, Goodwin NC, Haranahalli K, Huang R, Leftheris K, May-Dracka TL, Olson ME, Blanco MJ. Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI). J Med Chem 2023; 66:3651-3655. [PMID: 36884261 DOI: 10.1021/acs.jmedchem.3c00350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Abstract
On the occasion of the 2023 International Women's Day on March 8, 2023, we want to celebrate and highlight the contributions of many women volunteers in the American Chemical Society Division of Medicinal Chemistry (ACS MEDI).
Collapse
|
6
|
Candito DA, Simov V, Gulati A, Kattar S, Chau RW, Lapointe BT, Methot JL, DeMong DE, Graham TH, Kurukulasuriya R, Keylor MH, Tong L, Morriello GJ, Acton JJ, Pio B, Liu W, Scott JD, Ardolino MJ, Martinot TA, Maddess ML, Yan X, Gunaydin H, Palte RL, McMinn SE, Nogle L, Yu H, Minnihan EC, Lesburg CA, Liu P, Su J, Hegde LG, Moy LY, Woodhouse JD, Faltus R, Xiong T, Ciaccio P, Piesvaux JA, Otte KM, Kennedy ME, Bennett DJ, DiMauro EF, Fell MJ, Neelamkavil S, Wood HB, Fuller PH, Ellis JM. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. J Med Chem 2022; 65:16801-16817. [PMID: 36475697 DOI: 10.1021/acs.jmedchem.2c01605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Inhibition of leucine-rich repeat kinase 2 (LRRK2) kinase activity represents a genetically supported, chemically tractable, and potentially disease-modifying mechanism to treat Parkinson's disease. Herein, we describe the optimization of a novel series of potent, selective, central nervous system (CNS)-penetrant 1-heteroaryl-1H-indazole type I (ATP competitive) LRRK2 inhibitors. Type I ATP-competitive kinase physicochemical properties were integrated with CNS drug-like properties through a combination of structure-based drug design and parallel medicinal chemistry enabled by sp3-sp2 cross-coupling technologies. This resulted in the discovery of a unique sp3-rich spirocarbonitrile motif that imparted extraordinary potency, pharmacokinetics, and favorable CNS drug-like properties. The lead compound, 25, demonstrated exceptional on-target potency in human peripheral blood mononuclear cells, excellent off-target kinase selectivity, and good brain exposure in rat, culminating in a low projected human dose and a pre-clinical safety profile that warranted advancement toward pre-clinical candidate enabling studies.
Collapse
Affiliation(s)
- David A Candito
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Vladimir Simov
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Anmol Gulati
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Solomon Kattar
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Ryan W Chau
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Blair T Lapointe
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Joey L Methot
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Duane E DeMong
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Thomas H Graham
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Ravi Kurukulasuriya
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Mitchell H Keylor
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Ling Tong
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Gregori J Morriello
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - John J Acton
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Barbara Pio
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Weiguo Liu
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Jack D Scott
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Michael J Ardolino
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Theodore A Martinot
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Matthew L Maddess
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Xin Yan
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Hakan Gunaydin
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Rachel L Palte
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Spencer E McMinn
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Lisa Nogle
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Hongshi Yu
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Ellen C Minnihan
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Charles A Lesburg
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Ping Liu
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Jing Su
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Laxminarayan G Hegde
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Lily Y Moy
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Janice D Woodhouse
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Robert Faltus
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Tina Xiong
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Paul Ciaccio
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Jennifer A Piesvaux
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Karin M Otte
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Matthew E Kennedy
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | | | - Erin F DiMauro
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Matthew J Fell
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - Santhosh Neelamkavil
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Harold B Wood
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey07033, United States
| | - Peter H Fuller
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| | - J Michael Ellis
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts02115, United States
| |
Collapse
|
7
|
Keylor MH, Gulati A, Kattar SD, Johnson RE, Chau RW, Margrey KA, Ardolino MJ, Zarate C, Poremba KE, Simov V, Morriello GJ, Acton JJ, Pio B, Yan X, Palte RL, McMinn SE, Nogle L, Lesburg CA, Adpressa D, Lin S, Neelamkavil S, Liu P, Su J, Hegde LG, Woodhouse JD, Faltus R, Xiong T, Ciaccio PJ, Piesvaux J, Otte KM, Wood HB, Kennedy ME, Bennett DJ, DiMauro EF, Fell MJ, Fuller PH. Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors. J Med Chem 2021; 65:838-856. [PMID: 34967623 DOI: 10.1021/acs.jmedchem.1c01968] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to Parkinson's disease (PD), a disabling and progressive neurodegenerative disorder whose current therapies are limited in scope and efficacy. In this report, we describe a rigorous hit-to-lead optimization campaign supported by structural enablement, which culminated in the discovery of brain-penetrant, candidate-quality molecules as represented by compounds 22 and 24. These compounds exhibit remarkable selectivity against the kinome and offer good oral bioavailability and low projected human doses. Furthermore, they showcase the implementation of stereochemical design elements that serve to enable a potency- and selectivity-enhancing increase in polarity and hydrogen bond donor (HBD) count while maintaining a central nervous system-friendly profile typified by low levels of transporter-mediated efflux and encouraging brain penetration in preclinical models.
Collapse
Affiliation(s)
- Mitchell H Keylor
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Anmol Gulati
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Solomon D Kattar
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Rebecca E Johnson
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Ryan W Chau
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Kaila A Margrey
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Michael J Ardolino
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Cayetana Zarate
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Kelsey E Poremba
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Vladimir Simov
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Gregori J Morriello
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - John J Acton
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Barbara Pio
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xin Yan
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Rachel L Palte
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Spencer E McMinn
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Lisa Nogle
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Charles A Lesburg
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Donovon Adpressa
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Shishi Lin
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Santhosh Neelamkavil
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ping Liu
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Jing Su
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Laxminarayan G Hegde
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Janice D Woodhouse
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Robert Faltus
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Tina Xiong
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Paul J Ciaccio
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Jennifer Piesvaux
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Karin M Otte
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Harold B Wood
- Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Matthew E Kennedy
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | | | - Erin F DiMauro
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Matthew J Fell
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Peter H Fuller
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| |
Collapse
|
8
|
Simov V, Altman MD, Bianchi E, DelRizzo S, DiNunzio EN, Feng G, Goldenblatt P, Ingenito R, Johnson SA, Mansueto MS, Mayhood T, Mortison JD, Serebrov V, Sondey C, Sriraman V, Tucker TJ, Walji A, Wan H, Yue Y, Stoeck A, DiMauro EF. Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer. Eur J Med Chem 2021; 224:113686. [PMID: 34303079 DOI: 10.1016/j.ejmech.2021.113686] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 07/03/2021] [Accepted: 07/03/2021] [Indexed: 11/16/2022]
Abstract
Pathway activating mutations of the transcription factor NRF2 and its negative regulator KEAP1 are strongly correlative with poor clinical outcome with pemetrexed/carbo(cis)platin/pembrolizumab (PCP) chemo-immunotherapy in lung cancer. Despite the strong genetic support and therapeutic potential for a NRF2 transcriptional inhibitor, currently there are no known direct inhibitors of the NRF2 protein or its complexes with MAF and/or DNA. Herein we describe the design of a novel and high-confidence homology model to guide a medicinal chemistry effort that resulted in the discovery of a series of peptides that demonstrate high affinity, selective binding to the Antioxidant Response Element (ARE) DNA and thereby displace NRF2-MAFG from its promoter, which is an inhibitory mechanism that to our knowledge has not been previously described. In addition to their activity in electrophoretic mobility shift (EMSA) and TR-FRET-based assays, we show significant dose-dependent ternary complex disruption of NRF2-MAFG binding to DNA by SPR, as well as cellular target engagement by thermal destabilization of HiBiT-tagged NRF2 in the NCI-H1944 NSCLC cell line upon digitonin permeabilization, and SAR studies leading to improved cellular stability. We report the characterization and unique profile of lead peptide 18, which we believe to be a useful in vitro tool to probe NRF2 biology in cancer cell lines and models, while also serving as an excellent starting point for additional in vivo optimization toward inhibition of NRF2-driven transcription to address a significant unmet medical need in non-small cell lung cancer (NSCLC).
Collapse
Affiliation(s)
- Vladimir Simov
- Merck & Co., Inc., Chemistry, 33 Avenue Louis Pasteur, Boston, MA 02127, USA.
| | - Michael D Altman
- Merck & Co., Inc., Chemistry, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Elisabetta Bianchi
- Peptides and Small Molecules R&D, IRBM, Via Pontina, 30,600, 00071 Pomezia RM, Italy
| | - Sonia DelRizzo
- Peptides and Small Molecules R&D, IRBM, Via Pontina, 30,600, 00071 Pomezia RM, Italy
| | - Edward N DiNunzio
- Merck & Co., Inc., Chemistry, 2000 Galloping Hill Road, K-15, Kenilworth, NJ 07033, USA
| | - Guo Feng
- Merck & Co., Inc., Quantitative Biosciences, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Peter Goldenblatt
- Merck & Co., Inc., Quantitative Biosciences, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Raffaele Ingenito
- Peptides and Small Molecules R&D, IRBM, Via Pontina, 30,600, 00071 Pomezia RM, Italy
| | - Scott A Johnson
- Merck & Co., Inc., Chemistry, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - My Sam Mansueto
- Merck & Co., Inc., Quantitative Biosciences, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Todd Mayhood
- Merck & Co., Inc., Chemistry, 2000 Galloping Hill Road, K-15, Kenilworth, NJ 07033, USA
| | - Jonathan D Mortison
- Merck & Co., Inc., Chemistry, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Victor Serebrov
- Merck & Co., Inc., Quantitative Biosciences, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Christopher Sondey
- Merck & Co., Inc., Quantitative Biosciences, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Venkat Sriraman
- Merck & Co., Inc., Quantitative Biosciences, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Thomas J Tucker
- Merck & Co., Inc., Chemistry, 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Abbas Walji
- Merck & Co., Inc., Chemistry, 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Hui Wan
- Merck & Co., Inc., PPDM, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
| | - Yingzi Yue
- Merck & Co., Inc., Biology, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Alexander Stoeck
- Merck & Co., Inc., Biology, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| | - Erin F DiMauro
- Merck & Co., Inc., Chemistry, 33 Avenue Louis Pasteur, Boston, MA 02127, USA
| |
Collapse
|
9
|
Gulati A, Yeung CS, Lapointe B, Kattar SD, Gunaydin H, Scott JD, Childers KK, Methot JL, Simov V, Kurukulasuriya R, Pio B, Morriello GJ, Liu P, Tang H, Neelamkavil S, Wood HB, Rada VL, Ardolino MJ, Yan XC, Palte R, Otte K, Faltus R, Woodhouse J, Hegde LG, Ciaccio P, Minnihan EC, DiMauro EF, Fell MJ, Fuller PH, Ellis JM. Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. RSC Med Chem 2021; 12:1164-1173. [PMID: 34355182 DOI: 10.1039/d1md00097g] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 05/06/2021] [Indexed: 12/19/2022] Open
Abstract
The discovery of potent, kinome selective, brain penetrant LRRK2 inhibitors is the focus of extensive research seeking new, disease-modifying treatments for Parkinson's disease (PD). Herein, we describe the discovery and evolution of a picolinamide-derived lead series. Our initial optimization efforts aimed at improving the potency and CLK2 off-target selectivity of compound 1 by modifying the heteroaryl C-H hinge and linker regions. This resulted in compound 12 which advanced deep into our research operating plan (ROP) before heteroaryl aniline metabolite 14 was characterized as Ames mutagenic, halting its progression. Strategic modifications to our ROP were made to enable early de-risking of putative aniline metabolites or hydrolysis products for mutagenicity in Ames. This led to the discovery of 3,5-diaminopyridine 15 and 4,6-diaminopyrimidine 16 as low risk for mutagenicity (defined by a 3-strain Ames negative result). Analysis of key matched molecular pairs 17 and 18 led to the prioritization of the 3,5-diaminopyridine sub-series for further optimization due to enhanced rodent brain penetration. These efforts culminated in the discovery of ethyl trifluoromethyl pyrazole 23 with excellent LRRK2 potency and expanded selectivity versus off-target CLK2.
Collapse
Affiliation(s)
- Anmol Gulati
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Charles S Yeung
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Blair Lapointe
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Solomon D Kattar
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Hakan Gunaydin
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Jack D Scott
- Merck & Co., Inc. 2015 Galloping Hill Road Kenilworth New Jersey 07033 USA
| | - Kaleen K Childers
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Joey L Methot
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Vladimir Simov
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Ravi Kurukulasuriya
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Barbara Pio
- Merck & Co., Inc. 2015 Galloping Hill Road Kenilworth New Jersey 07033 USA
| | - Greg J Morriello
- Merck & Co., Inc. 2015 Galloping Hill Road Kenilworth New Jersey 07033 USA
| | - Ping Liu
- Merck & Co., Inc. 2015 Galloping Hill Road Kenilworth New Jersey 07033 USA
| | - Haiqun Tang
- Merck & Co., Inc. 2015 Galloping Hill Road Kenilworth New Jersey 07033 USA
| | | | - Harold B Wood
- Merck & Co., Inc. 2015 Galloping Hill Road Kenilworth New Jersey 07033 USA
| | - Vanessa L Rada
- Merck & Co., Inc. 770 Sumneytown Pike West Point Pennsylvania 19486 USA
| | - Michael J Ardolino
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Xin Cindy Yan
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Rachel Palte
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Karin Otte
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Robert Faltus
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Janice Woodhouse
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Laxminarayan G Hegde
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Paul Ciaccio
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Ellen C Minnihan
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Erin F DiMauro
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Matthew J Fell
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - Peter H Fuller
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| | - J Michael Ellis
- Merck & Co., Inc. 33 Avenue Louis Pasteur Boston Massachusetts 02115 USA +1 617 992 2472 +1 617 992 3113
| |
Collapse
|
10
|
Vara BA, Levi SM, Achab A, Candito DA, Fradera X, Lesburg CA, Kawamura S, Lacey BM, Lim J, Methot JL, Xu Z, Xu H, Smith DM, Piesvaux JA, Miller JR, Bittinger M, Ranganath SH, Bennett DJ, DiMauro EF, Pasternak A. Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds. ACS Med Chem Lett 2021; 12:653-661. [PMID: 33859804 PMCID: PMC8040257 DOI: 10.1021/acsmedchemlett.1c00096] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 03/15/2021] [Indexed: 12/13/2022] Open
Abstract
Hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase, is a negative immune regulator of T cell receptor (TCR) and B cell signaling that is primarily expressed in hematopoietic cells. Accordingly, it has been reported that HPK1 loss-of-function in HPK1 kinase-dead syngeneic mouse models shows enhanced T cell signaling and cytokine production as well as tumor growth inhibition in vivo, supporting its value as an immunotherapeutic target. Herein, we present the structurally enabled discovery of novel, potent, and selective diaminopyrimidine carboxamide HPK1 inhibitors. The key discovery of a carboxamide moiety was essential for enhanced enzyme inhibitory potency and kinome selectivity as well as sustained elevation of cellular IL-2 production across a titration range in human peripheral blood mononuclear cells. The elucidation of structure-activity relationships using various pendant amino ring systems allowed for the identification of several small molecule type-I inhibitors with promising in vitro profiles.
Collapse
Affiliation(s)
- Brandon A. Vara
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Samuel M. Levi
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Abdelghani Achab
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - David A. Candito
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Xavier Fradera
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Charles A. Lesburg
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Shuhei Kawamura
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Brian M. Lacey
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Jongwon Lim
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Joey L. Methot
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Zangwei Xu
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Haiyan Xu
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Dustin M. Smith
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Jennifer A. Piesvaux
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - J. Richard Miller
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Mark Bittinger
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Sheila H. Ranganath
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - David J. Bennett
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Erin F. DiMauro
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| | - Alexander Pasternak
- Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics
and Drug Metabolism, Oncology Early Discovery, Merck & Co.,
Inc., Boston, Massachusetts 02115, United States
| |
Collapse
|
11
|
Cheng AC, Doherty EM, Johnstone S, DiMauro EF, Dao J, Luthra A, Ye J, Tang J, Nixey T, Min X, Tagari P, Miranda LP, Wang Z. Structure-guided discovery of dual recognition chemibodies. Acta Crystallogr A Found Adv 2019. [DOI: 10.1107/s0108767319097836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
12
|
La DS, Peterson EA, Bode C, Boezio AA, Bregman H, Chu-Moyer MY, Coats J, DiMauro EF, Dineen TA, Du B, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Fremeau R, Huang X, Ilch C, Kornecook TJ, Kreiman C, Ligutti J, Jasmine Lin MH, McDermott JS, Marx I, Matson DJ, McDonough SI, Moyer BD, Nho Nguyen H, Taborn K, Yu V, Weiss MM. The discovery of benzoxazine sulfonamide inhibitors of Na V 1.7: Tools that bridge efficacy and target engagement. Bioorg Med Chem Lett 2017. [DOI: 10.1016/j.bmcl.2017.05.070] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
13
|
Sparling BA, DiMauro EF. Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors. Bioorg Med Chem Lett 2017; 27:3207-3218. [DOI: 10.1016/j.bmcl.2017.04.073] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2017] [Revised: 04/20/2017] [Accepted: 04/24/2017] [Indexed: 12/11/2022]
|
14
|
Chakka N, Andrews KL, Berry LM, Bregman H, Gunaydin H, Huang L, Guzman-Perez A, Plant MH, Simard JR, Gingras J, DiMauro EF. Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators. Eur J Med Chem 2017; 137:63-75. [PMID: 28575722 DOI: 10.1016/j.ejmech.2017.05.036] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/09/2017] [Accepted: 05/11/2017] [Indexed: 12/24/2022]
Abstract
Glycine receptors (GlyRs) are pentameric glycine-gated chloride ion channels that are enriched in the brainstem and spinal cord where they have been demonstrated to play a role in central nervous system (CNS) inhibition. Herein we describe two novel classes of glycine receptor potentiators that have been developed using similarity- and property-guided scaffold hopping enabled by parallel synthesis and pharmacophore-based virtual screening strategies. This effort resulted in the identification of novel, efficient and modular leads having favorable in vitro ADME profiles and high CNS multi-parameter optimization (MPO) scores, exemplified by azetidine sulfonamide 19 and aminothiazole sulfone (ent2)-20.
Collapse
Affiliation(s)
- Nagasree Chakka
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Kristin L Andrews
- Department of Molecular Engineering, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Loren M Berry
- Department of Pharmacokinetics, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Howard Bregman
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Hakan Gunaydin
- Department of Molecular Engineering, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Liyue Huang
- Department of Pharmacokinetics, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Angel Guzman-Perez
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Matthew H Plant
- Department of Discovery Attribute Sciences, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Jeffrey R Simard
- Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Jacinthe Gingras
- Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Erin F DiMauro
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA.
| |
Collapse
|
15
|
Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin MHJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. J Med Chem 2017; 60:5969-5989. [DOI: 10.1021/acs.jmedchem.6b01851] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Thomas Kornecook
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | - Joseph Ligutti
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | - Dong Liu
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bryan D. Moyer
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MHJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. J Med Chem 2017; 60:5990-6017. [DOI: 10.1021/acs.jmedchem.6b01850] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
| | | | - Jessica Able
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Thomas Kornecook
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | - Joseph Ligutti
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Bryan D. Moyer
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | |
Collapse
|
17
|
Sparling BA, Yi S, Able J, Bregman H, DiMauro EF, Foti RS, Gao H, Guzman-Perez A, Huang H, Jarosh M, Kornecook T, Ligutti J, Milgram BC, Moyer BD, Youngblood B, Yu VL, Weiss MM. Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V1.7 inhibitors. Medchemcomm 2017; 8:744-754. [PMID: 30108793 PMCID: PMC6072352 DOI: 10.1039/c6md00578k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Accepted: 11/30/2016] [Indexed: 11/21/2022]
Abstract
NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability.
Collapse
Affiliation(s)
- Brian A Sparling
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - S Yi
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - J Able
- Department of Neuroscience , Amgen Inc. , One Amgen Center Drive , Thousand Oaks , CA 91320 , USA
| | - H Bregman
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - Erin F DiMauro
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - R S Foti
- Department of Pharmacokinetics and Drug Metabolism , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA
| | - H Gao
- Department of Molecular Engineering, Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA
| | - A Guzman-Perez
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - H Huang
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - M Jarosh
- Department of Neuroscience , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA
| | - T Kornecook
- Department of Neuroscience , Amgen Inc. , One Amgen Center Drive , Thousand Oaks , CA 91320 , USA
| | - J Ligutti
- Department of Neuroscience , Amgen Inc. , One Amgen Center Drive , Thousand Oaks , CA 91320 , USA
| | - B C Milgram
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| | - B D Moyer
- Department of Neuroscience , Amgen Inc. , One Amgen Center Drive , Thousand Oaks , CA 91320 , USA
| | - B Youngblood
- Department of Neuroscience , Amgen Inc. , One Amgen Center Drive , Thousand Oaks , CA 91320 , USA
| | - V L Yu
- Department of Neuroscience , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA
| | - M M Weiss
- Department of Medicinal Chemistry , Amgen Inc. , 360 Binney Street , Cambridge , MA 02142 , USA .
| |
Collapse
|
18
|
Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MHJ, Liu D, McDermott JS, Moyer BD, Nguyen HN, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM. Correction to "Sulfonamides as Selective Na V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement". ACS Med Chem Lett 2017; 8:378. [PMID: 28337335 DOI: 10.1021/acsmedchemlett.7b00075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
[This corrects the article DOI: 10.1021/acsmedchemlett.6b00243.].
Collapse
|
19
|
Bregman H, Simard JR, Andrews KL, Ayube S, Chen H, Gunaydin H, Guzman-Perez A, Hu J, Huang L, Huang X, Krolikowski PH, Lehto SG, Lewis RT, Michelsen K, Pegman P, Plant MH, Shaffer PL, Teffera Y, Yi S, Zhang M, Gingras J, DiMauro EF. The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors. J Med Chem 2016; 60:1105-1125. [PMID: 28001399 DOI: 10.1021/acs.jmedchem.6b01496] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Current pain therapeutics suffer from undesirable psychotropic and sedative side effects, as well as abuse potential. Glycine receptors (GlyRs) are inhibitory ligand-gated ion channels expressed in nerves of the spinal dorsal horn, where their activation is believed to reduce transmission of painful stimuli. Herein, we describe the identification and hit-to-lead optimization of a novel class of tricyclic sulfonamides as allosteric GlyR potentiators. Initial optimization of high-throughput screening (HTS) hit 1 led to the identification of 3, which demonstrated ex vivo potentiation of glycine-activated current in mouse dorsal horn neurons from spinal cord slices. Further improvement of potency and pharmacokinetics produced in vivo proof-of-concept tool molecule 20 (AM-1488), which reversed tactile allodynia in a mouse spared-nerve injury (SNI) model. Additional structural optimization provided highly potent potentiator 32 (AM-3607), which was cocrystallized with human GlyRα3cryst to afford the first described potentiator-bound X-ray cocrystal structure within this class of ligand-gated ion channels (LGICs).
Collapse
Affiliation(s)
| | - Jeffrey R Simard
- Department of Neuroscience, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | | | | - Sonya G Lehto
- Department of Neuroscience, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | - Maosheng Zhang
- Department of Neuroscience, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | |
Collapse
|
20
|
Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MHJ, Liu D, McDermott JS, Moyer BD, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM. Sulfonamides as Selective Na V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement. ACS Med Chem Lett 2016; 7:1062-1067. [PMID: 27994738 DOI: 10.1021/acsmedchemlett.6b00243] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Accepted: 09/21/2016] [Indexed: 11/29/2022] Open
Abstract
Human genetic evidence has identified the voltage-gated sodium channel NaV1.7 as an attractive target for the treatment of pain. We initially identified naphthalene sulfonamide 3 as a potent and selective inhibitor of NaV1.7. Optimization to reduce biliary clearance by balancing hydrophilicity and hydrophobicity (Log D) while maintaining NaV1.7 potency led to the identification of quinazoline 16 (AM-2099). Compound 16 demonstrated a favorable pharmacokinetic profile in rat and dog and demonstrated dose-dependent reduction of histamine-induced scratching bouts in a mouse behavioral model following oral dosing.
Collapse
Affiliation(s)
- Isaac E. Marx
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Thomas A. Dineen
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jessica Able
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Christiane Bode
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Howard Bregman
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Margaret Chu-Moyer
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Erin F. DiMauro
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Bingfan Du
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Robert S. Foti
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Robert T. Fremeau
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Hua Gao
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Hakan Gunaydin
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Brian E. Hall
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Liyue Huang
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Thomas Kornecook
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Charles R. Kreiman
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Daniel S. La
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Joseph Ligutti
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Min-Hwa Jasmine Lin
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Dong Liu
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jeff S. McDermott
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Bryan D. Moyer
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Emily A. Peterson
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jonathan T. Roberts
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Paul Rose
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jean Wang
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Beth D. Youngblood
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Violeta Yu
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Matthew M. Weiss
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| |
Collapse
|
21
|
DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Bojic EF, Foti RS, Fremeau R, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, Kornecook T, Lee J, Ligutti J, Liu D, Moyer BD, Ortuno D, Rose PE, Schenkel LB, Taborn K, Wang J, Wang Y, Yu V, Weiss MM. Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. J Med Chem 2016; 59:7818-39. [DOI: 10.1021/acs.jmedchem.6b00425] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Robert Fremeau
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | - Thomas Kornecook
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | - Joseph Ligutti
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dong Liu
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bryan D. Moyer
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Matson DJ, Hamamoto DT, Bregman H, Cooke M, DiMauro EF, Huang L, Johnson D, Li X, McDermott J, Morgan C, Wilenkin B, Malmberg AB, McDonough SI, Simone DA. Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund's Adjuvant Models of Pain. PLoS One 2015; 10:e0138140. [PMID: 26379236 PMCID: PMC4575030 DOI: 10.1371/journal.pone.0138140] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 08/25/2015] [Indexed: 11/18/2022] Open
Abstract
While genetic evidence shows that the Nav1.7 voltage-gated sodium ion channel is a key regulator of pain, it is unclear exactly how Nav1.7 governs neuronal firing and what biophysical, physiological, and distribution properties of a pharmacological Nav1.7 inhibitor are required to produce analgesia. Here we characterize a series of aminotriazine inhibitors of Nav1.7 in vitro and in rodent models of pain and test the effects of the previously reported “compound 52” aminotriazine inhibitor on the spiking properties of nociceptors in vivo. Multiple aminotriazines, including some with low terminal brain to plasma concentration ratios, showed analgesic efficacy in the formalin model of pain. Effective concentrations were consistent with the in vitro potency as measured on partially-inactivated Nav1.7 but were far below concentrations required to inhibit non-inactivated Nav1.7. Compound 52 also reversed thermal hyperalgesia in the complete Freund’s adjuvant (CFA) model of pain. To study neuronal mechanisms, electrophysiological recordings were made in vivo from single nociceptive fibers from the rat tibial nerve one day after CFA injection. Compound 52 reduced the spontaneous firing of C-fiber nociceptors from approximately 0.7 Hz to 0.2 Hz and decreased the number of action potentials evoked by suprathreshold tactile and heat stimuli. It did not, however, appreciably alter the C-fiber thresholds for response to tactile or thermal stimuli. Surprisingly, compound 52 did not affect spontaneous activity or evoked responses of Aδ-fiber nociceptors. Results suggest that inhibition of inactivated states of TTX-S channels, mostly likely Nav1.7, in the peripheral nervous system produces analgesia by regulating the spontaneous discharge of C-fiber nociceptors.
Collapse
Affiliation(s)
- David J. Matson
- Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Darryl T. Hamamoto
- Department of Diagnostics and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, Minnesota, United States of America
| | - Howard Bregman
- Department of Medicinal Chemistry, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Melanie Cooke
- Department of Pharmaceutics Research & Development, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Erin F. DiMauro
- Department of Medicinal Chemistry, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Liyue Huang
- Department of Pharmacokinetics & Drug Metabolism, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Danielle Johnson
- Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Xingwen Li
- Department of Pharmacokinetics & Drug Metabolism, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Jeff McDermott
- Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Carrie Morgan
- Department of Pharmaceutics Research & Development, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Ben Wilenkin
- Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Annika B. Malmberg
- Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America
| | - Stefan I. McDonough
- Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America
- * E-mail:
| | - Donald A. Simone
- Department of Diagnostics and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, Minnesota, United States of America
| |
Collapse
|
23
|
Huang H, Acquaviva L, Bregman H, Buchanan J, Chakka N, DiMauro EF, Dovey J, Gunaydin H, Hua Z, Huang X, Huang L, Patel VF, Martin MW, Serafino R, Wilson C. Abstract 1621: Discovery of pyridyl pyrrolopyridinones as potent and selective CK1γ inhibitors. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-1621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The canonical Wnt pathway regulates the ability of β-catenin to activate specific target genes. Aberrant activation of the Wnt pathway is believed to drive the development and growth of many cancers; for example, APC mutations were observed in >80% of the sporadic colorectal cancers. The casein kinase 1 (CK1) family of serine/threonine protein kinases is highly conserved. Multiple members of the CK1 family are shown to regulate the Wnt pathway through interactions with various proteins. The central role of CK1γ in Wnt signal transduction makes it an attractive target for the treatment of Wnt-pathway dependent cancers. We employed a structure-based approach and identified a series of pyridyl pyrrolopyridinones as potent and selective CK1γ inhibitors. These compounds exhibited good enzyme and cell potency, as well as selectivity against other CK1 isoforms, and favorable rodent PK profiles. Oral dosing of optimized lead compounds resulted in significant inhibition of LRP6 phosphorylation in a mouse tumor PD model.
Citation Format: Hongbing Huang, Lisa Acquaviva, Howard Bregman, John Buchanan, Nagasree Chakka, Erin F. DiMauro, Jennifer Dovey, Hakan Gunaydin, Zihao Hua, Xin Huang, Liyue Huang, Vinod F. Patel, Matthew W. Martin, Randy Serafino, Cindy Wilson. Discovery of pyridyl pyrrolopyridinones as potent and selective CK1γ inhibitors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1621. doi:10.1158/1538-7445.AM2014-1621
Collapse
|
24
|
Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF. Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. ACS Med Chem Lett 2013; 4:1218-23. [PMID: 24900633 DOI: 10.1021/ml4003315] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 10/21/2013] [Indexed: 11/29/2022] Open
Abstract
Aberrant activation of the Wnt pathway has been implicated in the development and formation of many cancers. TNKS inhibition has been shown to antagonize Wnt signaling via Axin stabilization in APC mutant colon cancer cell lines. We employed structure-based design to identify a series of 2-aminopyridine oxazolidinones as potent and selective TNKS inhibitors. These compounds exhibited good enzyme and cell potency as well as selectivity over other PARP isoforms. Co-crystal structures of these 2-aminopyridine oxazolidinones complexed to TNKS reveal an induced-pocket binding mode that does not involve interactions with the nicotinamide binding pocket. Oral dosing of lead compounds 3 and 4 resulted in significant effects on several Wnt-pathway biomarkers in a three day DLD-1 mouse tumor PD model.
Collapse
Affiliation(s)
- Hongbing Huang
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Angel Guzman-Perez
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Lisa Acquaviva
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Virginia Berry
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Howard Bregman
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Jennifer Dovey
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Hakan Gunaydin
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Xin Huang
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Liyue Huang
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Doug Saffran
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Randy Serafino
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Steve Schneider
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Cindy Wilson
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Erin F. DiMauro
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
25
|
Bregman H, Chakka N, Guzman-Perez A, Gunaydin H, Gu Y, Huang X, Berry V, Liu J, Teffera Y, Huang L, Egge B, Mullady EL, Schneider S, Andrews PS, Mishra A, Newcomb J, Serafino R, Strathdee CA, Turci SM, Wilson C, DiMauro EF. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. J Med Chem 2013; 56:4320-42. [PMID: 23701517 DOI: 10.1021/jm4000038] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates β-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of β-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).
Collapse
Affiliation(s)
- Howard Bregman
- Department of Chemistry Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Bregman H, Gunaydin H, Gu Y, Schneider S, Wilson C, DiMauro EF, Huang X. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J Med Chem 2013; 56:1341-5. [PMID: 23316926 DOI: 10.1021/jm301607v] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Potent and selective inhibitors of tankyrases have recently been characterized to bind to an induced pocket. Here we report the identification of a novel potent and selective tankyrase inhibitor that binds to both the nicotinamide pocket and the induced pocket. The crystal structure of human TNKS1 in complex with this "dual-binder" provides a molecular basis for their strong and specific interactions and suggests clues for the further development of tankyrase inhibitors.
Collapse
Affiliation(s)
- Howard Bregman
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, USA
| | | | | | | | | | | | | |
Collapse
|
27
|
Huang H, Acquaviva L, Berry V, Bregman H, Chakka N, O’Connor A, DiMauro EF, Dovey J, Epstein O, Grubinska B, Goldstein J, Gunaydin H, Hua Z, Huang X, Huang L, Human J, Long A, Newcomb J, Patel VF, Saffran D, Serafino R, Schneider S, Strathdee C, Tang J, Turci S, White R, Yu V, Zhao H, Wilson C, Martin MW. Structure-Based Design of Potent and Selective CK1γ Inhibitors. ACS Med Chem Lett 2012; 3:1059-64. [PMID: 24900428 DOI: 10.1021/ml300278f] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2012] [Accepted: 10/18/2012] [Indexed: 12/20/2022] Open
Abstract
Aberrant activation of the Wnt pathway is believed to drive the development and growth of some cancers. The central role of CK1γ in Wnt signal transduction makes it an attractive target for the treatment of Wnt-pathway dependent cancers. We describe a structure-based approach that led to the discovery of a series of pyridyl pyrrolopyridinones as potent and selective CK1γ inhibitors. These compounds exhibited good enzyme and cell potency, as well as selectivity against other CK1 isoforms. A single oral dose of compound 13 resulted in significant inhibition of LRP6 phosphorylation in a mouse tumor PD model.
Collapse
Affiliation(s)
- Hongbing Huang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Lisa Acquaviva
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Virginia Berry
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Howard Bregman
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Nagasree Chakka
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Anne O’Connor
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Erin F. DiMauro
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jennifer Dovey
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Oleg Epstein
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Barbara Grubinska
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jon Goldstein
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Hakan Gunaydin
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Zihao Hua
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Xin Huang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Liyue Huang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jason Human
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Alex Long
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - John Newcomb
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Vinod F. Patel
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Doug Saffran
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Randy Serafino
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Steve Schneider
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Craig Strathdee
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jin Tang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Susan Turci
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Ryan White
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Violeta Yu
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Huilin Zhao
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Cindy Wilson
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Matthew W. Martin
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| |
Collapse
|
28
|
Hua Z, Huang X, Bregman H, Chakka N, DiMauro EF, Doherty EM, Goldstein J, Gunaydin H, Huang H, Mercede S, Newcomb J, Patel VF, Turci SM, Yan J, Wilson C, Martin MW. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorg Med Chem Lett 2012; 22:5392-5. [PMID: 22877629 DOI: 10.1016/j.bmcl.2012.07.046] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 07/10/2012] [Accepted: 07/12/2012] [Indexed: 11/29/2022]
Abstract
Screening of the Amgen compound library led to the identification of 2-phenylamino-6-cyano-1H-benzimidazole 1a as a potent CK1 gamma inhibitor with excellent kinase selectivity and unprecedented CK1 isoform selectivity. Further structure-based optimization of this series resulted in the discovery of 1h which possessed good enzymatic and cellular potency, excellent CK1 isoform and kinase selectivity, and acceptable pharmacokinetic properties.
Collapse
Affiliation(s)
- Zihao Hua
- Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Bregman H, Berry L, Buchanan JL, Chen A, Du B, Feric E, Hierl M, Huang L, Immke D, Janosky B, Johnson D, Li X, Ligutti J, Liu D, Malmberg A, Matson D, McDermott J, Miu P, Nguyen HN, Patel VF, Waldon D, Wilenkin B, Zheng XM, Zou A, McDonough SI, DiMauro EF. Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain. J Med Chem 2011; 54:4427-45. [DOI: 10.1021/jm200018k] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Howard Bregman
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Loren Berry
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - John L. Buchanan
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - April Chen
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bingfan Du
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Elma Feric
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Markus Hierl
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Liyue Huang
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - David Immke
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Brett Janosky
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Danielle Johnson
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Xingwen Li
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Joseph Ligutti
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dong Liu
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Annika Malmberg
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - David Matson
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jeff McDermott
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Peter Miu
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hanh Nho Nguyen
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Vinod F. Patel
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Daniel Waldon
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Ben Wilenkin
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Xiao Mei Zheng
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Anruo Zou
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Stefan I. McDonough
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Erin F. DiMauro
- Department of Chemistry Research and Discovery, ‡Department of Pharmacokinetics and Drug Metabolism, and §Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department of Lead Discovery, and ⊥Department of Neuroscience, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
30
|
DiMauro EF, Buchanan JL, Chen A, Emkey R, Hitchcock SA, Huang L, Huang MY, Janosky B, Lee JH, Li X, Martin MW, Tomlinson SA, White RD, Zheng XM, Patel VF, Fremeau RT. Corrigendum to “Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2” [Bioorg. Med. Chem. Lett. 18 (2008) 4267–4274]. Bioorg Med Chem Lett 2009. [DOI: 10.1016/j.bmcl.2008.07.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
DiMauro EF, Buchanan JL, Chen A, Emkey R, Hitchcock SA, Huang L, Huang MY, Janosky B, Lee JH, Li X, Martin MW, Tomlinson SA, White RD, Zheng XM, Patel VF, Fremeau RT. Erratum to “Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2” [Bioorg. Med. Chem. Lett. 18 (2008) 4267–4274]. Bioorg Med Chem Lett 2008. [DOI: 10.1016/j.bmcl.2008.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Cheng Y, Albrecht BK, Brown J, Buchanan JL, Buckner WH, DiMauro EF, Emkey R, Fremeau RT, Harmange JC, Hoffman BJ, Huang L, Huang M, Lee JH, Lin FF, Martin MW, Nguyen HQ, Patel VF, Tomlinson SA, White RD, Xia X, Hitchcock SA. Discovery and Optimization of a Novel Series of N-Arylamide Oxadiazoles as Potent, Highly Selective and Orally Bioavailable Cannabinoid Receptor 2 (CB2) Agonists. J Med Chem 2008; 51:5019-34. [DOI: 10.1021/jm800463f] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yuan Cheng
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Brian K. Albrecht
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - James Brown
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - John L. Buchanan
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - William H. Buckner
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Erin F. DiMauro
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Renee Emkey
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Robert T. Fremeau
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Jean-Christophe Harmange
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Beth J. Hoffman
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Liyue Huang
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Ming Huang
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Josie Han Lee
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Fen-Fen Lin
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Matthew W. Martin
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Hung Q. Nguyen
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Vinod F. Patel
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Susan A. Tomlinson
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Ryan D. White
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Xiaoyang Xia
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| | - Stephen A. Hitchcock
- Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, Chemistry Research and Discovery, Department of HTS and Molecular Pharmocology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Kendall Square Building 1000, Cambridge, Massachusetts 02139
| |
Collapse
|
33
|
DiMauro EF, Buchanan JL, Cheng A, Emkey R, Hitchcock SA, Huang L, Huang MY, Janosky B, Lee JH, Li X, Martin MW, Tomlinson SA, White RD, Zheng XM, Patel VF, Fremeau RT. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2. Bioorg Med Chem Lett 2008; 18:4267-74. [DOI: 10.1016/j.bmcl.2008.06.096] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2008] [Revised: 06/26/2008] [Accepted: 06/30/2008] [Indexed: 10/21/2022]
|
34
|
DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X. Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure–Activity Relationships, and Inhibition of in Vivo T Cell Activation. J Med Chem 2008; 51:1681-94. [DOI: 10.1021/jm7010996] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Erin F. DiMauro
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - John Newcomb
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Joseph J. Nunes
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Jean E. Bemis
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Christina Boucher
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Lilly Chai
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Stuart C. Chaffee
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Holly L. Deak
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Linda F. Epstein
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Ted Faust
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Paul Gallant
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Anu Gore
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Yan Gu
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Brad Henkle
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Faye Hsieh
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Xin Huang
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Joseph L. Kim
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Josie H. Lee
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Matthew W. Martin
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - David C. McGowan
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Daniela Metz
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Deanna Mohn
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Kurt A. Morgenstern
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Antonio Oliveira-dos-Santos
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Vinod F. Patel
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - David Powers
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Paul E. Rose
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Stephen Schneider
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Susan A. Tomlinson
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Yan-Yan Tudor
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Susan M. Turci
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Andrew A. Welcher
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Huilin Zhao
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Li Zhu
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| | - Xiaotian Zhu
- Department of Medicinal Chemistry, Department of Molecular Structure, and Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of HTS and Molecular Pharmacology, Department of Inflammation, Department of Pharmaceutics, and Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
| |
Collapse
|
35
|
Deak HL, Newcomb JR, Nunes JJ, Boucher C, Cheng AC, DiMauro EF, Epstein LF, Gallant P, Hodous BL, Huang X, Lee JH, Patel VF, Schneider S, Turci SM, Zhu X. N-(3-(Phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: Structure, synthesis and SAR. Bioorg Med Chem Lett 2008; 18:1172-6. [DOI: 10.1016/j.bmcl.2007.11.123] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2007] [Revised: 11/27/2007] [Accepted: 11/30/2007] [Indexed: 12/11/2022]
|
36
|
Martin MW, Newcomb J, Nunes JJ, Bemis JE, McGowan DC, White RD, Buchanan JL, DiMauro EF, Boucher C, Faust T, Hsieh F, Huang X, Lee JH, Schneider S, Turci SM, Zhu X. Erratum to “Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties” [Bioorg. Med. Chem. Lett. 17 (2007) 2299–2304]. Bioorg Med Chem Lett 2007. [DOI: 10.1016/j.bmcl.2007.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
DiMauro EF, Vitullo JR. Microwave-assisted preparation of fused bicyclic heteroaryl boronates: application in one-pot Suzuki couplings. J Org Chem 2007; 71:3959-62. [PMID: 16674073 DOI: 10.1021/jo060218p] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The rapid and efficient synthesis of various disubstituted 5,6-fused heterocycles using a microwave-assisted one-pot cyclization-Suzuki coupling approach is described. This work highlights the tolerance of the boronic ester functional group to a variety of reaction conditions and the utility of functionalized boronates as penultimate intermediates in the synthesis of diverse compound libraries.
Collapse
Affiliation(s)
- Erin F DiMauro
- Department of Chemistry Research and Discovery, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, USA.
| | | |
Collapse
|
38
|
DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cheng A, Faust T, Hsieh F, Huang X, Lee JH, Marshall TL, Martin MW, McGowan DC, Schneider S, Turci SM, White RD, Zhu X. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR. Bioorg Med Chem Lett 2007; 17:2305-9. [PMID: 17280833 DOI: 10.1016/j.bmcl.2007.01.057] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2006] [Revised: 01/12/2007] [Accepted: 01/18/2007] [Indexed: 10/23/2022]
Abstract
4-Amino-5,6-biaryl-furo[2,3-d]pyrimidines were identified as potent non-selective inhibitors of Lck. A novel, divergent, and practical synthetic route was developed to access derivatives from bifunctional intermediates. Lead optimization was guided by X-ray crystallographic data, and preliminary SAR led to the identification of compounds with improved cellular potency and selectivity.
Collapse
Affiliation(s)
- Erin F DiMauro
- Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Martin MW, Newcomb J, Nunes JJ, Bemis JE, McGowan DC, White RD, Buchanan JL, DiMauro EF, Boucher C, Faust T, Hsieh F, Huang X, Lee JH, Schneider S, Turci SM, Zhu X. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. Bioorg Med Chem Lett 2007; 17:2299-304. [PMID: 17276681 DOI: 10.1016/j.bmcl.2007.01.048] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2006] [Revised: 01/12/2007] [Accepted: 01/12/2007] [Indexed: 11/18/2022]
Abstract
2,3-Diarylfuro[2,3-b]pyridine-4-amines are a novel class of potent and selective inhibitors of Lck. The discovery, synthesis, and structure activity relationships of this series of inhibitors are reported. The most promising compounds were also profiled to deduce their pharmacokinetic properties.
Collapse
Affiliation(s)
- Matthew W Martin
- Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2006; 49:5671-86. [PMID: 16970394 DOI: 10.1021/jm0605482] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED(50) of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.
Collapse
Affiliation(s)
- Erin F DiMauro
- Department of Medicinal Chemistry, Amgen, Inc., Cambridge, Massachusetts 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Fennie MW, DiMauro EF, O'Brien EM, Annamalai V, Kozlowski MC. Mechanism and scope of salen bifunctional catalysts in asymmetric aldehyde and α-ketoester alkylation. Tetrahedron 2005. [DOI: 10.1016/j.tet.2005.03.117] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Annamalai V, DiMauro EF, Carroll PJ, Kozlowski MC. Catalysis of the Michael addition reaction by late transition metal complexes of BINOL-derived salens. J Org Chem 2003; 68:1973-81. [PMID: 12608819 DOI: 10.1021/jo025993t] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Salen metal complexes incorporating two chiral BINOL moieties have been synthesized and characterized by X-ray crystallography. The X-ray structures show that this new class of Ni-BINOL-salen catalysts contains an unoccupied apical site for potential coordination of an electrophile and naphthoxides that are independent from the Lewis acid center. These characteristics allow independent alteration of the Lewis acidic and Brønsted basic sites. These unique complexes have been shown to catalyze the Michael reaction of dibenzyl malonate and cyclohexenone with good selectivity (up to 90% ee) and moderate yield (up to 79% yield). These catalysts are also effective in the Michael reaction between other enones and malonates. Kinetic data show that the reaction is first order in the Ni*Cs-BINOL-salen catalyst. Further experiments probed the reactivity of the individual Lewis acid and Brønsted base components of the catalyst and established that both moieties are essential for asymmetric catalysis. All told, the data support a bifunctional activation pathway in which the apical Ni site of the Ni*Cs-BINOL-salen activates the enone and the naphthoxide base activates the malonate.
Collapse
Affiliation(s)
- Venkatachalam Annamalai
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, USA
| | | | | | | |
Collapse
|
43
|
Affiliation(s)
- Erin F. DiMauro
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| | - Ahmed Mamai
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| | - Marisa C. Kozlowski
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| |
Collapse
|
44
|
Abstract
[formula: see text] The first catalytic, enantioselective addition of organoznic reagents to alpha-ketoesters is described. Modular bifunctional salen catalysts that contain Lewis acid and Lewis base activating groups accelerate the carbonyl addition to a much greater extent than the competing carbonyl reduction. alpha-Hydroxyesters containing new quaternary stereogenic centers are obtained in high yield and moderate enantiomeric excess. Enrichment to 98% ee can be effected by recrystallization of the corresponding alpha-hydroxy acid.
Collapse
Affiliation(s)
- Erin F DiMauro
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | |
Collapse
|
45
|
Abstract
Lewis acid-Lewis base salen complexes have been identified as highly efficient catalysts for the addition of dialkylzincs to alpha-ketoesters. In contrast to aldehydes or ketones, the reaction between diethylzinc and alpha-ketoesters is significant in the absence of catalyst. In the presence of catalyst, the reaction rate is increased over 100-fold relative to the background. Furthermore, the reduction product, which is a major coproduct with other catalysts, is not observed with these bifunctional salens. As a result, high yields of the addition products can be obtained (57-99%). Both the Lewis acid and Lewis base portions of the catalyst are critical to the reactivity and selectivity. The two separate portions of the catalyst have been shown to function in a cooperative manner.
Collapse
Affiliation(s)
- Erin F DiMauro
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia 19104-6323, USA
| | | |
Collapse
|
46
|
|
47
|
Affiliation(s)
- Erin F. DiMauro
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| | - Marisa C. Kozlowski
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| |
Collapse
|
48
|
Abstract
A set of modular bifunctional salen catalysts which contain Lewis acid and Lewis base activating groups is described. These groups can be altered independently to control nucleophilic and electrophilic activation of the reacting substrates. These salen-derived catalysts show enhanced reactivity in the addition of diethylzinc to aldehydes with respect to most other salen, amino alcohol, and diamine derived catalysts and reactivity comparable to that of Ti complexes of bis-sulfonamides and diols. Structure: see text.
Collapse
Affiliation(s)
- E F DiMauro
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | |
Collapse
|
49
|
Abstract
Salen metal complexes incorporating two chiral BINOL moieties have been synthesized and characterized crystallographically. The corresponding bisnaphthoxide complexes have been found to catalyze the asymmetric addition of benzyl malonate to cyclohexenone in up to 90% ee. With these modular catalysts, the Lewis acid and Bronsted base portions can be independently altered.
Collapse
Affiliation(s)
- E F DiMauro
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | |
Collapse
|